GATC Biotech Offers World's Fastest Exome Sequencing Service: 1-Week Exome Diagnostic

(PresseBox) ( Konstanz, Germany, )
GATC Biotech, the European leader for DNA sequencing, has designed InView(TM) 1-Week Exome Diagnostic especially for diagnostic purposes. This service enables early detection of multiple genetic variants presumably responsible for diverse genetic disease markers within just 7 days, the world's fastest turn-around time available. With its DIN EN ISO/IEC 17025 certified Next Gen Sequencing laboratories, GATC Biotech offers this application e.g. for detection of cancerous cells or early detection of other genetic diseases.

The application supports clinicians to initiate urgent treatments and opens the way to a more personalised patient care in the field of cancer, metabolic dysfunctions and immunological diseases. With a combination of standardised workflows and highest quality standards, InView(TM) 1-Week Exome Diagnostic is an overall solution for fast and reliable variant detection. Focusing on the functional relevant coding regions, only approx. 1% of the human genome (the exome) needs to be sequenced. This provides an efficient advantage for diagnostics and clinical research.

"Next Generation Sequencing technologies have set a new level in the field of clinical research and diagnostics. 1-Week Exome Diagnostic is an all-in-one service delivering rapid results for early detection of diseases for our customers in diagnostics, clinical and pharmaceutical research", tells Dr. Marcus Benz, COO at GATC Biotech. "Being the leading service provider for NGS solutions, scientists can profit from our thorough experience in exome analysis while receiving accurate results in only 7 days."

Essential requirements for the competence of analysis and calibration laboratories such as DIN EN ISO/IEC 17025 and DIN EN ISO 9001 by the national accreditation body for the Federal Republic of Germany (DAkkS) have been fulfilled by GATC Biotech's NGS laboratories. The application is based on Agilent SureSelectXT Human All Exon V5 enrichment and Illumina MiSeq.
The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to service@pressebox.de.